Immunogenicity of protein therapeutics

• Published in: Trends in immunology Vol. 28; no. 11; pp. 482 - 490
• Main Authors: De Groot, Anne S., Scott, David W.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.11.2007; Elsevier Limited
• Subjects: Allergy and Immunology; Animals; Antibodies - immunology; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; B-Lymphocytes - immunology; Cross Reactions; Drug dosages; Histocompatibility Antigens Class II - immunology; Humans; Immune system; Immune Tolerance; Immunoassay - methods; Ligands; Lymphocyte Activation; Lymphocytes; Majority stockholders; Medical research; Protein Engineering - methods; Proteins; Proteins - immunology; Proteins - therapeutic use; Recombinant Proteins - immunology; Recombinant Proteins - therapeutic use; Regulation; Studies; T-Lymphocytes - immunology; Vaccines

Protein therapeutics, such as monoclonal antibodies, enzymes and toxins, hold significant promise for improving human health. However, repeated administration of protein therapeutics, whether natural or recombinant, often leads to the induction of undesirable anti-drug antibodies (ADAs), which inter...